Lead Cancer Vaccine Candidate
Cold Tumors (unspecified solid tumors)
Phase 1Active
Key Facts
About ErVimmune
ErVimmune is a private, clinical-stage biotech founded in 2019, headquartered in Paris, France, with a lab presence in Lyon. The company is pioneering a novel approach to cancer immunotherapy by targeting HERV-derived antigens, aiming to convert immunologically 'cold' tumors into 'hot' ones responsive to treatment. With a €17 million Series A first closing in early 2026, it is advancing its lead cancer vaccine candidate into clinical development. Its strategy is supported by a proprietary AI and proteomics platform and peer-reviewed scientific validation.
View full company profile